Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0EPYFC
ADC Name
SAR-428926
Synonyms
SAR 428926; SAR-428926; SAR42 8926; SAR428926
   Click to Show/Hide
Organization
ImmunoGen, Inc.; Sanofi
Drug Status
Phase 1 (Terminated)
Indication
In total 6 Indication(s)
Breast cancer
Phase 1
Clinical Trial
Colorectal cancer
Phase 1
Clinical Trial
Gastric cancer
Phase 1
Clinical Trial
Lung cancer
Phase 1
Clinical Trial
Ovarian cancer
Phase 1
Clinical Trial
Prostate cancer
Phase 1
Clinical Trial
Drug-to-Antibody Ratio
Undisclosed
Structure
Antibody Name
Undisclosed
Antigen Name
Lysosome-associated membrane glycoprotein 1 (LAMP1)
  Antigen Info 
Payload Name
Mertansine DM4
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)
  Linker Info 
Conjugate Type
Random Lysines
Combination Type
ravtansine
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT02575781
Phase 1
A first-in-human phase 1 dose escalation study of SAR428926 in patients with advanced solid tumors.
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Related Clinical Trial
NCT Number NCT02575781  Clinical Status Phase 1
Clinical Description A first-in-human phase 1 dose escalation study of SAR428926 in patients with advanced solid tumors.
References
Ref 1 A First-in-human Phase 1 Dose Escalation Study of SAR428926 in Patients With Advanced Solid Tumors